Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society

NEXT STORY
Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
PREV STORY
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma Reports Second Quarter 2018 Financial Results and Provides Update on Operations

Key Highlights: Top-line results from confirmatory Phase III study with TALICIA® for H. pylori ...

author_avatar
NASDAQ Market News

Immunohistochemistry: Worldwide Market Insights & Projections 2019-2023 — The Increasing Involvement of Stakeholders is Driving Growth

author_avatar
NASDAQ Market News

Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma

BERKELEY, Calif., May 17, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical ...

author_avatar
NASDAQ Market News